About: Kinetics and Isotype Assessment of Antibodies Targeting the Spike Protein Receptor Binding Domain of SARS-CoV-2 In COVID-19 Patients as a function of Age and Biological Sex.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Kinetics and Isotype Assessment of Antibodies Targeting the Spike Protein Receptor Binding Domain of SARS-CoV-2 In COVID-19 Patients as a function of Age and Biological Sex. Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Kinetics and Isotype Assessment of Antibodies Targeting the Spike Protein Receptor Binding Domain of SARS-CoV-2 In COVID-19 Patients as a function of Age and Biological Sex.
Creator	Bruce, Emily Diehl, Sean Crothers, Jessica An, Gary Kirkpatrick, Beth Botten, Stapleton, Renee Graham, Nancy Mcelvany, Benjamin Miles, Ashley Poynter, Matthew Strother, Camilla Whitaker, Annalis
Source	MedRxiv; Medline
abstract	SARS-CoV-2 is the newly emerged virus responsible for the global COVID-19 pandemic. There is an incomplete understanding of the host humoral immune response to SARS-CoV-2 during acute infection. Host factors such as age and sex as well the kinetics and functionality of antibody responses are important factors to consider as vaccine development proceeds. The receptor-binding domain of the CoV spike (RBD-S) protein is important in host cell recognition and infection and antibodies targeting this domain are often neutralizing. In a cross-sectional study of anti-RBD-S antibodies in COVID-19 patients we found equivalent levels in male and female patients and no age-related deficiencies even out to 93 years of age. The anti-RBD-S response was evident as little as 6 days after onset of symptoms and for at least 5 weeks after symptom onset. Anti-RBD-S IgG, IgM, and IgA responses were simultaneously induced within 10 days after onset, but isotype-specific kinetics differed such that anti-RBD-S IgG was most sustained over a 5-week period. The kinetics and magnitude of neutralizing antibody formation strongly correlated with that seen for anti-RBD-S antibodies. Our results suggest age- and sex- related disparities in COVID-19 fatalities are not explained by anti-RBD-S responses. The multi-isotype anti-RBD-S response induced by live virus infection could serve as a potential marker by which to monitor vaccine-induced responses.
has issue date	2020-07-22(xsd:dateTime)
bibo:doi	10.1101/2020.07.15.20154443
bibo:pmid	32743592
has license	medrxiv
sha1sum (hex)	5d9ff0925da09027f5968e70fc489e348dcdef72
schema:url	https://doi.org/10.1101/2020.07.15.20154443
resource representing a document's title	Kinetics and Isotype Assessment of Antibodies Targeting the Spike Protein Receptor Binding Domain of SARS-CoV-2 In COVID-19 Patients as a function of Age and Biological Sex.
has PubMed identifier	32743592
schema:publication	medRxiv : the preprint server for health sciences
resource representing a document's body	covid:5d9ff0925da09027f5968e70fc489e348dcdef72#body_text
is schema:about of	named entity 'All rights reserved' named entity 'spike' named entity 'Spike' named entity 'Biological' named entity 'Protein' named entity 'Receptor' named entity 'COVID-19' named entity 'INCOMPLETE' named entity 'acute infection' named entity 'responsible' named entity 'cell' named entity 'host' named entity 'SARS-CoV-2' named entity 'responses' named entity 'protein' named entity 'acute infection' named entity 'host cell' named entity 'RBD' named entity 'COVID-19' named entity 'Receptor' named entity 'RBD' named entity 'IgM' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'antigen' named entity 'RBD' named entity 'medRxiv' named entity 'IgM' named entity 'RBD' named entity 'peer review' named entity 'risk factors' named entity 'IgG' named entity 'RBD' named entity 'SARS-CoV-2' named entity 'serology' named entity 'RBD' named entity 'peer review' named entity 'infection' named entity 'RBD' named entity 'RBD' named entity 'cell membrane' named entity 'IgG1' named entity 'medRxiv' named entity 'SARS-CoV-2' named entity 'cellular receptors' named entity 'correlation' named entity 'RBD' named entity 'C-terminal' named entity 'SARS-CoV-2' named entity 'cellular receptors' named entity 'serology' named entity 'filter paper' named entity 'serum' named entity 'middle east respiratory syndrome' named entity 'antibody' named entity 'IgM' named entity 'IgA' named entity 'RBD' named entity 'COVID' named entity 'polyclonal' named entity 'antibody isotype' named entity 'passive immunotherapy' named entity 'plasma' named entity 'SARS' named entity 'vaccine' named entity 'RBD' named entity 'morbidity' named entity 'trimer' named entity 'peer-reviewed' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software